New drug combination tested in older cancer Patients' transplants
NCT ID NCT01453088
Summary
This study compared two different stem cell transplant approaches for people aged 60+ with multiple myeloma, a blood cancer. Researchers tested whether adding a drug called bortezomib to the standard transplant chemotherapy would help patients live longer without their cancer worsening. The trial was stopped early and enrolled 63 participants before termination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20057, United States
Conditions
Explore the condition pages connected to this study.